Basecamp Research has secured $140 million (£106 million) in Series C funding to expand its AI-powered strategy for developing treatments for diseases previously considered untreatable. The company’s method focuses on modifying a patient’s cells to correct damage at a genetic level, avoiding the constraints of conventional drug development processes.
S32 led the oversubscribed round, with contributions from Menlo Ventures’ Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Additional investment comes from senior leaders from across pharma, BioTech and global industry, including André Hoffmann, vice-chairman of Roche. Hoffmann described the approach as a defining shift in medicine, drawing parallels to the biotechnology advancements of the last half-century.
The company’s technology merges EDEN, its biological foundation model, with custom DNA-editing tools to produce therapies capable of integrating with a patient’s genetic code. Existing cell-based treatments often cost hundreds of thousands per patient and offer limited complexity. Basecamp’s system aims to make cell therapies more sophisticated, more customisable, and simpler to administer, with potential to transform how we treat cancer, autoimmune disease, and more.
Underpinning EDEN is the Trillion Gene Atlas, the world’s largest proprietary biological database. Collaboratively developed with partners such as NVIDIA, Anthropic, PacBio and Ultima Genomics, it compiles genetic information from over 30 countries across every continent. Unlike specialized AI systems, EDEN is engineered to interpret DNA patterns across all living organisms, allowing it to propose therapeutic solutions directly from disease-related data.
Basecamp has already produced preclinical findings across multiple disease categories. To speed up industry partnerships, the company appointed Richard Pearce, a former Biogen executive, as chief business officer. Andy Conrad, who previously led Google’s Verily and now serves as a general partner at S32, joined the board, reinforcing the company’s vision to transform medicine through AI and biological insights.